DAOIB+Omega-3
Phase 2Small molecule
DAOIB+Omega-3 is one of 32 small molecule programs targeting Dementia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Dementia
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Ritalin
NovartisApproved
Namenda
AbbVieApproved
Exelon
NovartisApproved
Lexapro
AbbVieApproved
Keppra
UCBApproved
Dayvigo
EisaiApproved
Celexa
AbbVieApproved
Brintellix
TakedaApproved
Risperdal
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dementia1 trial
NMDA Enhancement Combined With Omega-3 for Early Dementia
Not yet recruiting·—·Phase 2·NCT05181189·140 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DAOIB+Omega-3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CChang Gung Memorial Hospital